Cannabis Science Development Team Recommends Patent Filings for Its Cannabis Processing and Drug Delivery Systems
SAN FRANCISCO--(BUSINESS WIRE)--Cannabis Science Inc. (NASD OTCBB: CBIS), an emerging pharmaceutical cannabis company, announced today that patent filings are expected for two of its key innovations. "The Drug Development Team members recognize the importance of having our first cannabis-based medicine covered, not just by one patent, but by two," Dr. Mary J. Ruwart, Vice President, Research & Development explained. A competitor can sometimes engineer a way around a single patent. Patenting both the manufacturing process as well as the delivery system virtually guarantees that our product will be immune to invasion by a competing company.
Cannabis Science CEO, Steve Kubby, is the inventor who will assign both of his patents to Cannabis Science. "Our new manufacturing process allows for the rapid and uniform harvesting of cannabis trichomes, are the part of the plant containing the active ingredient, THC," Kubby told potential investors today. "Just as the cotton gin made cotton harvesting economically feasible, our innovative process will revolutionize trichome harvesting."
"Having a creative mind like Steve Kubby at the helm gives us a competitive advantage," Dr. Robert Melamede, Chief Scientific Officer commented. "The new manufacturing process is only the tip of the proverbial iceberg. The unique drug delivery system he has designed enhances the stability and uniform absorption of the active ingredient. We expect our first product to outshine the competition with rapid---and prolonged---blood levels of THC."
Cannabis Science management has authorized expenditures for patents; the two described above will be the company's first official filings. "Naturally, Cannabis Science will use both of its discoveries for its own drug production," Chief Financial Officer, Richard Cowan said. "However, other firms will likely want to license these inventions for their own use as well. Cannabis Science will be able to supply other companies with superior trichome preparations or provide our unique drug delivery systems for other pharmaceutical preparations. The entire industry, the American public, and, of course, Cannabis Science and its investors, will reap the benefits."
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of medical marijuana research and development. The company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. It is dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," "intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.